Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions

International Journal of Technology Assessment in Health Care

Volumn 27, Issue 1, 2011, Pages 71-76

  Cleemput, Irina ^a,b   Neyt, Mattias ^b   Thiry, Nancy ^b   De Laet, Chris ^b   Leys, Mark ^b,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cost effectiveness Analysis; Decision making; Healthcare costs; Healthcare rationing economics; Quality adjusted life years

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COST-EFFECTIVENESS RATIOS; DECISION MAKING PROCESS; HEALTH-CARE DECISIONS; HEALTH-CARE SYSTEM; HEALTHCARE COSTS; HEALTHCARE SERVICES; POLICY MAKERS; POLICY MAKING; QUALITY-ADJUSTED LIFE YEARS; QUANTITATIVE DECISION; RELATIVE IMPORTANCE; SOCIAL SECURITY SYSTEMS; THEORETICAL FOUNDATIONS; THRESHOLD APPROACH; VALUE FOR MONIES;

COST EFFECTIVENESS; COSTS; DECISION MAKING; HEALTH CARE; SECURITY SYSTEMS;

COST BENEFIT ANALYSIS;

ARTICLE; CLINICAL DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; MEDICAL LITERATURE; MEDICAL PRACTICE; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; THEORY; COST BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE ORGANIZATION; MANAGEMENT; REVIEW; THEORETICAL MODEL;

COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE RATIONING; HUMANS; MODELS, THEORETICAL; POLICY MAKING; QUALITY-ADJUSTED LIFE YEARS;

EID: 79955698411     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310001194     Document Type: Article

References (33)

1. Bleichrodt H, Diecidue E, Quiggin J. Equity weights in the allocation of health care: The rank-dependent QALY model. J Health Econ. 2004;23:157-171. (Pubitemid 38199906)
2. Brouwer WB, Koopmanschap MA. On the economic foun¬dations of CEA. Ladies and gentlemen, take your positions! J Health Econ. 2000;19:439-459. (Pubitemid 30323797)
3. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc. 2006;4:20.
4. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for cost-effectiveness in health care. Belgian Health Care Knowledge Centre. HTA reports. Brussels: KCE; 2008:88.
5. Coast J. Is economic evaluation in touch with society's health values? BMJ. 2004;329:1233-1236. (Pubitemid 39551449)
6. Culyer A, McCabe C, Briggs A, et al. Searching for a threshold, not setting one: The role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. 2007;12:56-58. (Pubitemid 46174208)
7. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A bi¬nary choice analysis. Health Econ. 2004;13:437-452. (Pubitemid 38660393)
8. Dolan P. Utilitarianism and the measurement and aggregation of quality-adjusted life years. Health Care Anal. 2001;9:65-76. (Pubitemid 32397372)
9. Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisa¬tion and people's preferences: A methodological review of the literature. Health Econ. 2005;14:197-208. (Pubitemid 40253634)
10. Dolan P, Edlin R, Tsuchiya A. The relative societal value of health gains to different beneficiaries. http://www.pcpoh.bham. ac.uk/publichealth/ methodology/projects/RM03-JH11- PD.shtml(accessed 2008).
11. Dowie J. Why cost-effectiveness should trump (clinical) effec¬tiveness: The ethical economics of the South West quadrant. Health Econ. 2004;13:453-459. (Pubitemid 38660394)
12. Drummond M, Brown R, Fendrick AM, et al. Use of phar-macoeconomics information-report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health. 2003;6:407-416. (Pubitemid 36929727)
13. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care pro¬grammes (3rd ed.). Oxford: Oxford University Press; 2005.
14. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): The silence of the lambda. Soc Sci Med. 2006;62:2091-2100.
15. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health. 2007;28:365-391. (Pubitemid 46833348)
16. Hoffmann C, Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. Health Policy. 2000;52:179-192. (Pubitemid 30336269)
17. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation. Med Decis Making. 2005;25:667-677. (Pubitemid 41667135)
18. Mitton C, Donaldson C. Health care priority setting: Principles, practice and challenges. Cost Eff Resour Alloc. 2004;2:3
19. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008:80.
20. Raftery J. NICE and the challenge of cancer drugs. BMJ. 2009;338:b67.
21. Raftery J. Should NICE's threshold range for cost per QALY be raised? No. BMJ. 2009;338:b185.
22. Rawlins MD, Culyer AJ. National Institute for Clinical Excel¬lence and its value judgments. BMJ. 2004;329:224-227. (Pubitemid 39013284)
23. Stolk EA, van Donselaar G, Brouwer WB, Busschbach JJ. Rec¬onciliation of economic concerns and health policy: Illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics. 2004;22:1097-1107. (Pubitemid 39665341)
24. Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening. Int J Technol Assess Health Care. 2009;25:161-170.
25. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ. 2009;338:b181.
26. Tsuchiya A, Dolan P. The QALY model and individual prefer¬ences for health states and health profiles over time: A system¬atic review of the literature. Med Decis Making. 2005;25:460-467. (Pubitemid 41023173)
27. Tsuchiya A, Dolan P. Equality of what in health? Distinguishing between outcome egalitarianism and gain egalitarianism. Health Econ. 2009;18:147-159.
28. van der Zee J, Kroneman MW. Bismarck or Beveridge: A beauty contest between dinosaurs. BMC Health Serv Res. 2007;7:94.
29. Weinstein M, Zeckhauser R. Critical ratios and efficient alloca¬tion. Journal of Public Economics. 1973;2:147-157.
30. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721. (Pubitemid 8066534)
31. Williams A. Is the QALY a technical solution to a political problem? Of course not! Int J Health Serv. 1991;21:365-369; discussion 371-372.
32. Williams A. What could be nicer than NICE? London: Office of Health Economics; 2004.
33. Williams I, Bryan S, McIver S. How should cost-effectiveness analysis be used in health technology coverage decisions? Ev¬idence from the National Institute for Health and Clinical Ex¬cellence approach. J Health Serv Res Policy. 2007;12:73-79. (Pubitemid 46733207)